A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac
A phase 3 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.
Overview
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) is a phase 3 interventional study registered as NCT06742996 by BeOne Medicines, with 300 participants planned, started 2025-03-05 and due to reach its primary completion in 2028-08-31. Interventions recorded: Sonrotoclax, Zanubrutinib, Placebo. Conditions listed: Mantle Cell Lymphoma, B Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- TrialStudy of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Shares Sonrotoclax, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene).
- TrialA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene).
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene).
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Sonrotoclax, Zanubrutinib, BeOne Medicines (formerly BeiGene).
- TrialA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
- TrialStudy of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma